We recently demonstrated that soluble forms of the amyloid-β protein precursor (sAβPP) assemble into multimeric complexes in cerebrospinal fluid (CSF), which contributes to the underestimation of specific sAβPP species when assessed by ELISA. To circumvent this issue, we analyzed by SDS-PAGE large fragments of sAβPP and their variants in the CSF from Alzheimer’s disease (AD; n = 20) and control (n = 20) subjects, probing with specific antibodies against particular domains. Similar levels of sAβPPα and sAβPPβ protein were found in CSF samples from AD and controls, yet there appeared to be a shift in the balance of the soluble full-length AβPP (sAβPPf) species in AD samples, with a decrease in the proportion of the lower (∼100 kDa) band relative to the upper (∼120 kDa) band. Similar differences were observed in the contribution of the major KPI-immunoreactive AβPP species. CSF samples also displayed differences in the correlations of AβPP species with classical AD biomarkers, particularly with respect to the Aβ42 peptide. The differences reveal alterations that probably reflect pathophysiological changes in the brain.
HaassC, KaetherC, ThinakaranG, SisodiaS (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med2, a006270.
5.
BushAI, MartinsRN, RumbleB, MoirR, FullerS, MilwardE, CurrieJ, AmesD, WeidemannA, FischerP (1990) The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem265, 15977–15983.
6.
EfthimiopoulosS, VassilacopoulouD, RipellinoJA, TezapsidisN, RobakisNK (1996) Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proc Natl Acad Sci U S A93, 8046–8050.
7.
Cuchillo-IbañezI, Lopez-FontI, Boix-AmorósA, BrinkmalmG, BlennowK, MolinuevoJL, Sáez-ValeroJ (2015) Heteromers of amyloid precursor protein in cerebrospinal fluid. Mol Neurodegener10, 2.
8.
OlssonB, LautnerR, AndreassonU, ÖhrfeltA, PorteliusE, BjerkeM, HölttäM, RoséC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF and blood biomarkers for Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol15, 673–684.
9.
TanakaS, NakamuraS, UedaK, KameyamaM, ShiojiriS, TakahashiY, KitaguchiN, ItoH (1988) Three types of amyloid protein precursor mRNA in human brain: Their differential exression in Alzheimer’s disease. Biochem Biophys Res Commun157, 472–479.
10.
EvinG, LiQX (2012) Platelets and Alzheimer’s disease: Potential of APP as a biomarker. World J Psychiatry2, 102–113.
11.
PalmertMR, SiedlakSL, PodlisnyMB, GreenbergB, SheltonER, ChanHW, UsiakM, SelkoeDJ, PerryG, YounkinSG (1989) The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Natl Acad Sci U S A86, 6338–6342.
12.
PriorR, MönningU, Schreiter-GasserU, WeidemannA, BlennowK, GottfriesCG, MastersCL, BeyreutherK (1991) Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett124, 69–73.
13.
HanssonO, ZetterbergH, BuchhaveP, LondosE, BlennowK, MinthonL (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol5, 228–234.
14.
PalmqvistS, ZetterbergH, BlennowK, VestbergS, AndreassonU, BrooksDJ, OweniusR, HägerströmD, WollmerP, MinthonL, HanssonO (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol71, 1282–1289.
15.
LewczukP, Kamrowski-KruckH, PetersO, HeuserI, JessenF, PoppJ, BürgerK, HampelH, FrölichL, WolfS, PrinzB, JahnH, LuckhausCh, PerneczkyR, HüllM, SchröderJ, KesslerH, PantelJ, GertzHJ, KlafkiHW, KölschH, ReulbachU, EsselmannH, MalerJM, BiblM, KornhuberJ, WiltfangJ (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: A multicenter study. Mol Psychiatry15, 138–145.
16.
MoirRD, LynchT, BushAI, WhyteS, HenryA, PortburyS, MulthaupG, SmallDH, TanziRE, BeyreutherK, MastersCL (1988) Relative increase in Alzheimer’s disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. J Biol Chem273, 5013–5019.
17.
RefoloLM, SaltonSR, AndersonJP, MehtaP, RobakisNK (1989) Nerve and epidermal growth factors induce the release of the Alzheimer amyloid precursor from PC 12 cell cultures. Biochem Biophys Res Commun164, 664–670.
18.
Van NostrandWE, FarrowJS, WagnerSL, BhasinR, GoldgaberD, CotmanCW, CunninghamDD (1991) The predominant form of the amyloid beta-protein precursor in human brain is protease nexin 2. Proc Natl Acad Sci U S A88, 10302–10306.
19.
Van NostrandWE, WagnerSL, ShankleWR, FarrowJS, DickM, RozemullerJM, KuiperMA, WoltersEC, ZimmermanJ, CotmanCW (1992) Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A89, 2551–2555.
20.
LannfeltL, BasunH, WahlundLO, RoweBA, WagnerSL (1995) Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer’s disease. Nat Med1, 829–832.
21.
SennvikK, FastbomJ, BlombergM, WahlundLO, WinbladB, BenedikzE (2000) Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett278, 169–172.
BrinkmalmG, BrinkmalmA, BourgeoisP, PerssonR, HanssonO, PorteliusE, MerckenM, AndreassonU, ParentS, LipariF, OhrfeltA, BjerkeM, MinthonL, ZetterbergH, BlennowK, NutuM (2013) Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer’s disease. Brain Res1513, 117–126.
27.
LewczukP, PoppJ, LelentalN, KölschH, MaierW, KornhuberJ, JessenF (2012) Cerebrospinal fluid soluble amyloid-beta protein precursor as a potential novel biomarkers of Alzheimer’s disease. J Alzheimers Dis28, 119–125.
28.
PerneczkyR, TsolakidouA, ArnoldA, Diehl-SchmidJ, GrimmerT, FörstlH, KurzA, AlexopoulosP (2011) CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology77, 35–38.
29.
TavernaM, StraubT, HampelH, RujescuD, LichtenthalerSF (2013) A new sandwich immunoassay for detection of the alpha-secretase cleaved, soluble amyloid-beta protein precursor in cerebrospinal fluid and serum. J Alzheimers Dis37, 667–668.
30.
GabelleA, RocheS, GényC, BennysK, LabaugeP, TholanceY, QuadrioI, TiersL, GorB, ChauletC, VighettoA, CroisileB, Krolak-SalmonP, TouchonJ, Perret-LiaudetA, LehmannS (2010) Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res1357, 175–183.
31.
SavageMJ, HolderDJ, WuG, KaplowJ, SiuciakJA, PotterWZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer’s Disease Neuroimaging Initiative (2015) Soluble BACE-1 activity and sAβPPβ concentrations in Alzheimer’s disease and age-matched healthy control cerebrospinal fluid from the Alzheimer’s Disease Neuroimaging Initiative-1 baseline cohort. J Alzheimers Dis46, 431–440.
32.
HartlD, GuW, MayhausM, PichlerS, SchöpeJ, WagenpfeilS, RiemenschneiderM (2015) Amyloid-β protein precursor cleavage products in postmortem ventricular cerebrospinal fluid of Alzheimer’s disease patients. J Alzheimers Dis47, 365–372.
33.
AndrewRJ, KellettKA, ThinakaranG, HooperNM (2016) A Greek tragedy: The growing complexity of Alzheimer amyloid precursor protein proteolysis. J Biol Chem291, 19235–19244.
34.
GhisoJ, TagliaviniF, TimmersWF, FrangioneB (1989) Alzheimer’s disease amyloid precursor protein is present in senile plaques and cerebrospinal fluid: Immunohistochemical and biochemical characterization. Biochem Biophys Res Commun163, 430–437.
35.
PorteliusE, BrinkmalmG, TranA, AndreassonU, ZetterbergH, Westman-BrinkmalmA, BlennowK, OhrfeltA (2010) Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. Exp Neurol223, 351–358.
36.
VellaLJ, CappaiR (2012) Identification of a novel amyloid precursor protein processing pathway that generates secreted N-terminal fragments. FASEB J26, 2930–2940.
37.
ZhangZ, SongM, LiuX, Su KangS, DuongDM, SeyfriedNT, CaoX, ChengL, SunYE, Ping YuS, JiaJ, LeveyAI, YeK (2015) Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease. Nat Commun6, 8762.
BuxbaumJD, ThinakaranG, KoliatsosV, O’CallahanJ, SluntHH, PriceDL, SisodiaSS (1998) Alzheimer amyloid protein precursor in the rat hippocampus: Transport and processing through the perforant path. J Neurosci18, 9629–9637.
40.
WeidemannA, KönigG, BunkeD, FischerP, SalbaumJM, MastersCL, BeyreutherK (1989) Identification, biogenesis, and localization of precursors of Alzheimer’s disease A4 amyloid protein. Cell57, 115–126.
41.
van Waalwijk van DoornLJ, Koel-SimmelinkMJ, HaußmannU, KlafkiH, StruyfsH, LinningP, KnölkerHJ, TwaalfhovenH, KuiperijHB, EngelborghsS, ScheltensP, VerbeekMM, VanmechelenE, WiltfangJ, TeunissenCE (2016) Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. J Neurochem137, 112–121.
42.
PadovaniA, PastorinoL, BorroniB, ColciaghiF, RozziniL, MonasteroR, PerezJ, PettenatiC, MussiM, ParrinelloG, CottiniE, LenziGL, TrabucchiM, CattabeniF, Di LucaM (2001) Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD. Neurology57, 2243–2248.
43.
JanssenL, SobottF, De DeynPP, Van DamD (2015) Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. MethodsX2, 112–123.
